检测铜绿假单胞菌金属β-内酰胺酶方法比较

目的：探讨检测金属β-内酰胺酶的可靠方法。方法：收集临床分离耐亚胺培南的铜绿假单胞菌8株及产IMP-1金属争内酰胺酶标准株一株,分别采用纸片增效法和双纸片协同实验检测金属酶表型,比较其结果。结果和结论：纸片增效法容易出现假阳性结果,而纸片协同法是相对可靠的检测金属酶的方法。     

老年人亚胺培南耐药铜绿假单胞菌耐药性研究

目的 明确我院老年病人临床分离铜绿假单胞菌的耐药性、同源性及耐碳青霉烯菌株的基因型。方法 收集我院2006年5月-2009年5月自临床老年病人分离的262株铜绿假单胞菌,纸片扩散法测定其对16种抗菌药物的耐药性;琼脂稀释法和E test法测定耐碳青霉烯菌株对14种抗菌药物的MIC值,PCR扩增及克隆测序分析金属酶基因型。脉冲场凝胶电泳(PFGE)分析携带金属酶基因型菌株的同源性。结果 262株铜绿假单胞菌中筛选到104株耐碳青霉烯。104株耐碳青霉烯铜绿假单胞菌对氨苄西林/舒巴坦、头孢哌酮/舒巴坦两个含舒巴坦制剂药物耐药率分别为78.9％和35.9％,对多黏菌素E耐药率最低为6.0％,对米诺环素耐药率58.3％,其余抗菌药物耐药率均大于70.0％;104株亚胺培南耐药铜绿假单胞菌中12株携带金属酶基因,10株检测到有携带VIM-2基因的1类整合子。PFGE分型中12株菌株属于5个克隆株。结论 在我院流行的亚胺培南耐药铜绿假单胞菌中,金属酶基因不是最主要的基因型,金属β-内酰胺酶均为VIM-2型金属酶,耐药基因盒分布于不同的1类整合子中,整合子播散是最主要的流行方式。     

泛耐药鲍曼不动杆菌整合子Ⅰ和ISCR1结构及基因分型研究

目的研究从临床分离的鲍曼不动杆菌的整合子Ⅰ和ISCR1的分布及结构情况,并对其进行基因分型。方法分离自临床的57株鲍曼不动杆菌,PCR检测整合酶Ⅰ、整合子Ⅰ、ISCR1以及ISCR1可变区,PCR产物进行限制性片段长度多态性（RFLP）分型并进行测序分析可变区携带的耐药基因盒,ERIC-PCR进行基因分型。结果 49株整合酶I阳性,其中47株整合子I扩增阳性,RFLP分为2型,测序结果为aacA4-catB8-aadA1和drf17-aadA5。3株ISCR1以及ISCR1可变区扩增均阳性,可变区经RFLP分为1型,测序结果为orf513-qnrA1-ampR-qacEdeltal,ISCR1阳性菌整合子I均阳性,经ERIC-PCR检测将57株鲍曼不动杆菌分为27个基因型。结论Ⅰ类整合子广泛存在于鲍曼不动杆菌中,ISCRI携带率较低,氨基糖苷类、甲氧苄啶类和β-内酰胺类耐药基因盒较常见,ERIC-PCR可用于临床鲍曼不动杆菌的分子流行病学研究。     

儿科对碳青霉烯类耐药铜绿假单胞菌产金属酶的研究

目的 了解目前儿科对碳青霉烯类抗生素耐药铜绿假单胞菌产金属酶的情况。方法 本研究收集了2003年12月至2005年11月，北京儿童医院住院患儿中分离出对碳青霉烯类抗生素耐药的铜绿假单胞菌59株。使用E试验法检测金属酶的耐药表型，PCR技术检测编码金属酶的IMP、VIM、SPM和GIM4种基因型。结果 本研究59株对碳青霉烯类抗生素耐药铜绿假单胞菌中，29株金属酶耐药表型结果阳性，占49．2％。39株金属酶基因型阳性，占66．1％，其中扩增出IMP型阳性35株，占89．7％，VIM型阳性4株，占10．3％。未检测出SPM和GIM型金属酶。对哌拉西林、哌拉西林-他唑巴坦产金属酶不敏感率高于非产金属酶菌株，差异有统计学意义（P〈0．05）。对产金属酶菌株β-内酰胺类抗生素头孢噻肟、头孢哌酮、头孢他啶、头孢吡肟、头孢哌酮-舒巴坦的MIC90均达到256μg／ml，MIC90均大于256μg／ml，高于非产金属酶菌株。结论 从本研究分离的菌株显示儿科铜绿假单胞菌产金属酶率高于成人报道，产金属酶是儿科分离对碳青霉烯类抗生素耐药铜绿假单胞菌的重要耐药机制。且以产IMP型金属酶为主，少部分产VIM型金属酶。产金属酶菌株对β-内酰胺类抗生素耐药比非产金属酶菌株更严重，尤其对哌拉西林和哌拉西林-他唑巴坦耐药性高。E试验法易用于铜绿假单胞菌产金属酶的初步筛选，但不能单独作为检测铜绿假单胞菌产生金属酶的确证性试验。     

耐亚胺培南铜绿假单胞菌金属β-内酰胺酶和oprD2 基因的检测

目的: 了解我院临床分离下呼吸道感染的耐亚胺培南铜绿假单胞菌(IRPA) oprD2 基因和金属β-内酰胺酶(MBL)的分子流行病学情况。方法: 铜绿假单胞菌的鉴定和药敏采用VITEK-2系统进行药物的最低抑菌浓度(MIC)检测。应用双纸片增效法和聚合酶链反应(PCR)方法检测其产MBL的表型及相关的 oprD2 基因、IMP型和VIM型金属酶基因。结果: 157株亚胺培南铜绿假单胞菌对多种抗菌药物的耐药率均在40%以上,经双纸片增效法筛选出20株MBL阳性(12.7%),经PCR方法检测20株MBL阳性株中有13株IMP型基因阳性, oprD2 基因有67株阳性,其余90株缺失(57.3%),未发现VIM型基因。有10株IRPA既携带IMP型基因同时又有 oprD2 基因缺失。结论: 我院临床分离下呼吸道感染的耐亚胺培南铜绿假单胞菌呈较严重的多重耐药。IMP型基因是我院IRPA产MBL的主要基因型; oprD2 基因缺失可能是铜绿假单胞菌亚胺培南耐药的重要原因之一。     

转座子tnpU基因在多重耐药革兰阴性杆菌中的分布情况

目的研究转座子tnpU基因和β-内酰胺酶在多重耐药革兰阴性杆菌中的分布情况。方法用纸片扩散初筛试验、扩散确证试验进行超广谱β-内酰胺酶（ESBLs）表型检查,头孢西丁三维试验进行AmpC β-内酰胺酶的表型检查,纸片协同试验筛选产金属β-内酰胺酶（MBL）菌株;用多重聚合酶链反应（PCR）技术扩增转座子tnpU基因,并进行DNA测序;用MIC药敏法分析多重耐药革兰阴性杆菌的药物敏感性。结果转座子tnpU的总检出率为25．5％。在各菌种的检出率分别为大肠埃希菌占6.3％（3株）、肺炎克雷伯菌占8．3％（1株）、鲍曼不动杆菌占33-3％（20株）、铜绿假单胞菌占43．2％（16株）;β-内酰胺酶表型检测中,ESBLs的检出率最高,转座子tnpU基因阳性的菌株大多数B．内酰胺酶表型为阳性;转座子tnpU基因阳性菌株对抗生素的耐药率显著高于转座子阴性菌株（P〈0．05）。结论转座子tnpU基因在非发酵菌中的分布较广泛,可能在多重耐药机制中起重要作用。     

医院泛耐药鲍曼不动杆菌对碳青霉烯抗生素的耐药机制

目的 探讨医院泛耐药鲍曼不动杆菌对碳青霉烯抗生素的耐药机制.方法 应用PCR方法对2010年12月至2012年3月期间本院从临床痰标本中分离的36株泛耐药鲍曼不动杆菌进行碳青霉烯酶IMP、OXA23基因和整合子基因检测;提取细菌膜蛋白行SDS-PAGE电泳分析其组成.结果 36株泛耐药鲍曼不动杆菌碳青霉烯酶OXA23基因扩增均为阳性;14株碳青霉烯酶IMP基因扩增阳性,22株阴性.12株整合子PCR产物约1200 bp,10株约3000 bp,14株整合子PCR产物约3500 bp.与碳青霉烯抗生素敏感鲍曼不动杆菌膜蛋白比较,22株泛耐药鲍曼不动杆菌存在相对分子质量为25 000、36 000的膜蛋白缺失.结论 医院泛耐药鲍曼不动杆菌耐碳青霉烯抗生素机制与产IMP、OXA23碳青霉烯酶及膜蛋白缺失有关.     

汕头地区耐亚胺培南铜绿假单胞菌耐药分析

目的：了解汕头地区对亚胺培南耐药的铜绿假单胞菌（PA）的耐药情况及耐药机制。方法：收集临床分离耐亚胺培南的PA共141株，双纸片协同实验检测金属酶表型，PCR法检测外膜孔蛋白OprD2和金属β内酰胺酶（IMP、VIM、SPM）基因。结果：耐亚胺培南的铜绿假单胞菌均为多重耐药茵，对头孢哌酮／舒巴坦的耐药率较低，未发现产金属酶菌株，仅22株菌株扩增出OprD2基因。结论：头孢哌酮／舒巴坦可作为本地区临床治疗耐亚胺培南铜绿假单胞茵所致感染的首选经验用药，OprDa表达减少或不表达可能是临床分离铜绿假单胞茵对亚胺培南耐药的主要机制。     

临床分离耐喹诺酮类铜绿假单胞菌gyrA基因单点突变研究

目的 研究临床分离铜绿假单胞菌耐喹诺酮类药物的分子机制，对PCR－RFLP－SSCP分析铜绿假单胞菌gyrA基因突变的可行性评价。方法 以铜绿假单胞菌gyrA基因序列为靶序列，用PCR、PCR－SSCP、PCR－RFLP、DNA测序、OMIGA软件分析等方法，对铜绿假单胞菌gyrA基因突变进行研究。结果 在铜绿假单胞菌10株耐药突变株中，有8株的gyrA基因的83位表现出高频的单点突变，其突变方式全为ACC→ATC。gyrA的PCR扩增产物Sac Ⅱ酶切片段与测序结果一致。SSCP带谱与测序结果比较，除1株（PSA2）其SSCP带谱与标准株相同，但测序结果有点突变外，其余菌株与测序结果一致。结论 临床分离的铜绿假单胞菌耐喹诺酮类药物分子机制主要表现为gyrA基因83位氨基酸密码子突变（Thr-83→Ile)，利用PCR－SSPC－RFLP系统，可快速、准确地检测耐喹诺酮类药物的铜绿假单胞菌gyrA中至少1个碱基的差异。     

多重耐药铜绿假单胞菌超广谱β-内酰胺酶分析

目的 对多重耐药铜绿假单胞菌产β－内酰胺酶进行分析。方法 用E－试验和三相水解试验分析46株常规药敏试验全部耐药的铜绿假单胞菌的耐药表型，并用PCR扩增和产物测序方法检测其中可能产β－内酰胺酶的情况。结果 46株中8株产超广谱β－内酰胺酶，经分子生物学方法证实有blaVEB-1基因，同时还有D类酶blaOXA-10基因；46株中5株为持续高产AmpC酶；1株产生1种既能水解亚胺培南，又能被氯唑西林抑制的酶。结论 我院多重耐药铜绿假单胞菌所产β－内酰胺酶以超广谱β－内酰胺酶（8／46同时有blaVEB-1基因和blaOXA-10基因）和持续高产AmpC酶（5／46）为主。     

多重聚合酶链反应技术快速鉴定鲍曼不动杆菌

目的建立快速鉴定鲍曼不动杆菌菌株的方法。方法本研究建立多重PCR实验技术快速鉴定170株醋酸钙-鲍曼不动杆菌复合体以及对照组的其他菌属14株。结果138株菌的PCR产物扩增出2条条带,为鲍曼不动杆菌,另外32株只扩增出1条条带,为醋酸钙-鲍曼不动杆菌复合体的其他基因型,对照组的菌株没有扩增出条带。结论多重PCR技术的建立为快速鉴定鲍曼不动杆菌提供了一个快速而简便的方式。     

2012年深圳市光明新区人民医院细菌耐药监测

目的了解2012年深圳市光明新区人民医院临床分离菌对常用抗菌药物的耐药性。方法采用Microscanauto4鉴定及药敏系统对临床常规细菌进行监测．按CLSl2009年版标准判断药敏结果．并用WHONET5．4软件统计分析。结果全年共分离细菌1818株,其中革兰阳性菌占35．6％,革兰阴性菌占58．O％。葡萄球菌中耐甲氧西林金黄色葡萄球菌（MRSA）占18．3％,凝固酶阴性葡萄球菌（MRCNS）占71．9％。肺炎链球菌中青霉素非敏感的肺炎链球菌（PNSSP）占20．7％。大肠埃希菌和肺炎克雷伯杆菌产ESBLs菌株分别占43．2％和22．4％。检出5株亚胺培南耐药的肠杆科细菌。铜绿假单胞菌和鲍曼不动杆菌对头孢他啶、哌拉西林、妥布霉素、阿米卡星、环丙沙星、亚胺培南的耐药率均低于10％。结论本院常见致病菌耐药性不是十分严重,尤其是院内感染的铜绿假单胞菌和鲍曼不动杆菌对常用抗菌药物耐药率较低。     

Comparison of one-tube multiplex PCR, automated ribotyping and intergenic spacer (ITS) sequencing for rapid identification of Acinetobacter baumannii

Acinetobacter baumannii has emerged as a serious cause of nosocomial infections. Rapid identification of this pathogen is required so that appropriate therapy can be given and outbreaks controlled. This study evaluated a multiplex PCR and an automated ribotyping system for the rapid identification of Acinetobacter baumannii. In total, 22 different reference strains and 138 clinical isolates of Acinetobacter spp., identified by 16S-23S rRNA intergenic spacer (ITS) sequence analysis, were evaluated. All A. baumannii isolates (82 clinical isolates and one reference strain) were identified by the multiplex PCR method (specificity 100%). The sensitivity and specificity of the ribotyping system for identification of A. baumannii were 85.5% (71/83) and 93.5% (72/77), respectively. An additional 100 clinical isolates belonging to the Acinetobacter calcoaceticus-A. baumannii complex were used to compare these two methods for identification of A. baumannii, and this comparison revealed a level of disagreement of 14% (14 isolates). The accuracy of the multiplex PCR was 100%, which was confirmed by sequence analysis of the ITS and recA gene of these isolates. Thus, the multiplex PCR method dramatically increased the efficiency and speed of A. baumannii identification.     

Use of real-time PCR with multiple targets to identify Pseudomonas aeruginosa and other nonfermenting gram-negative bacilli from patients with cystic fibrosis

Pseudomonas aeruginosa and other gram-negative isolates from patients with cystic fibrosis (CF) may be difficult to identify because of their marked phenotypic diversity. We examined 200 gram-negative clinical isolates from CF respiratory tract specimens and compared identification by biochemical testing and real-time PCR with multiple different target sequences using a standardized combination of biochemical testing and molecular identification, including 16S rRNA partial sequencing and gyrB PCR and sequencing as a "gold standard." Of 50 isolates easily identified phenotypically as P. aeruginosa, all were positive with PCR primers for gyrB or oprI, 98% were positive with exotoxin A primers, and 90% were positive with algD primers. Of 50 P. aeruginosa isolates that could be identified by basic biochemical testing, 100% were positive by real-time PCR with gyrB or oprI primers, 96% were positive with exotoxin A primers, and 92% were positive with algD primers. For isolates requiring more-extensive biochemical evaluation, 13 isolates were identified as P. aeruginosa; all 13 were positive with gyrB primers, 12 of 13 were positive with oprI primers, 11 of 13 were positive with exotoxin A primers, and 10 of 13 were positive with algD primers. A single false-positive P. aeruginosa result was seen with oprI primers. The best-performing commercial biochemical testing was in exact agreement with molecular identification only 60% of the time for this most difficult group. Real-time PCR had costs similar to those of commercial biochemical testing but a much shorter turnaround time. Given the diversity of these CF isolates, real-time PCR with a combination of two target sequences appears to be the optimum choice for identification of atypical P. aeruginosa and for non-P. aeruginosa gram-negative isolates.     

Doripenem vs meropenem against Pseudomonas and Acinetobacter

Recently, doripenem has been approved for the treatment of nosocomial pneumonia (NP), including ventilator-associated pneumonia (VAP). The E-test was performed to determine the MICs of doripenem and meropenem in 203 endotracheal aspirate isolates that consisted of 140 Acinetobacter calcoaceticus-Acinetobacter baumannii complexes and 63 Pseudomonas aeruginosa. Doripenem showed minimum concentration necessary for inhibition of 50% (MIC 50 ) of P. aeruginosa isolates at 0.38 mg/L which is several times (84.2 times) lower than the corresponding MIC 50 value of >32 mg/L for meropenem. The MIC 50 and MIC 90 were similar for both the drugs against A. baumannii. Thus, P. aeruginosa was consistently more susceptible than the A. baumannii.     

Emergence and spread of carbapenem-resistant strains of Acinetobacter baumannii in a tertiary-care hospital in Poland

This study analysed the occurrence of carbapenem resistance among Acinetobacter baumannii isolates from a tertiary-care hospital in Poland, together with the molecular epidemiology of these isolates and the risk-factors for their acquisition and possible nosocomial spread. The medical charts of 21 patients with Acinetobacter infection or colonisation revealed that A. baumannii isolates were obtained most frequently from intensive care unit and surgical patients (particularly those receiving transplantation surgery). First isolation occurred, on average, on day 21 following admission (range 5-45 days). Infection with Acinetobacter contributed directly to the death of seven patients. Several patients were infected with more than one strain, and molecular typing revealed the co-circulation of three predominant clones, of which two belonged to the Acinetobacter lineages designated as European clones I and II. All three clones encoded an OXA-51-type carbapenemase, but were negative for carbapenemases belonging to the OXA-23, OXA-24 and OXA-58 families. The OXA-51 gene was found in both resistant and susceptible isolates, and was not associated directly with carbapenem resistance. Etests with imipenem and imipenem plus EDTA indicated production of a metallo-beta-lactamase (MBL) in carbapenem-resistant isolates. PCRs for IMP-type MBLs were negative, but PCR using consensus primers for VIM-type MBLs were positive for carbapenem-resistant isolates belonging to the European clone II lineage. The occurrence of a VIM-type MBL in association with one of the epidemic lineages of A. baumannii is a cause for concern. Further studies are needed to evaluate possible inter-hospital spread of resistant A. baumannii strains in Poland.     

重症监护病房下呼吸道感染的病原菌分布及耐药性分析

目的探讨重症监护病房（ICU）患者下呼吸道感染病原菌的分布及耐药性,为临床防治提供科学依据。方法整理分析我院ICU2003年1月至2007年12月下呼吸道感染患者痰培养的1146株病原菌．采用CLSI推荐的K．B法进行药敏试验。并对其耐药性进行分析。结果分离出的1146株病原菌中。革兰阴性杆菌占64．1％,革兰阳性球菌占28．4％。前5位病原菌依次为金黄色葡萄球菌、铜绿假单胞菌、鲍曼不动杆菌、洋葱伯克霍尔德菌、肺炎克雷伯菌。铜绿假单胞菌、鲍曼不动杆菌对亚胺培南耐药率分别为37．8％、10．6％,肺炎克雷伯菌、大肠埃希菌产超广谱β内酰胺酶（ESBLs）的检出率分别是68．5％、83．7％,肠杆菌科菌对亚胺培南全部敏感。未检出耐万古霉素的革兰阳性球菌。结论ICU下呼吸道感染以革兰阴性杆菌为主,病原菌耐药性严重。临床治疗应根据药敏试验结果。合理应用抗生素。     

三种检测铜绿假单胞菌AmpC酶方法的评价

目的探讨一种简便易行，适用于临床微生物实验室常规开展检测AmpCβ内酰胺酶（简称AmpC酶）的方法。方法对临床分离的150株铜绿假单胞菌用表型筛选试验作AmpC酶测定，对AmpC酶阳性菌株同时进行氯唑西林双纸片协同试验、氟氯西林（FCC）双抑制剂扩散协同试验、PCR基因检测。用基因检测来评价比较三种测定方法的检出率及差异。结果表型筛选试验AmpC酶阳性37株同时进行氯唑西林双纸片协同试验、氟氯西林双抑制剂扩散协同试验、基因检测，检测出阳性株分别为15、14、11株，阳性率分别是40．54％（15／37）、37．84％（14／37）、29．73％（11／37）。表型筛选试验与后三种方法比较差异有统计学意义（P〈0．01），后三种方法结果比较差异无统计学意义（P〉0．05）。结论氯唑西林双纸片协同试验、氟氯西林双抑制剂扩散协同试验检测AmpC酶特异性较表型筛选试验高，且操作简便、结果可靠，适合临床实验室常规检测应用。